Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
ID: 347576Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347576

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-168.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)" aimed at stimulating research in the discovery and development of novel small molecules for psychiatric disorders. The objective is to support the development and validation of screening assays that can lead to innovative biological models and screening techniques relevant to mental health conditions such as depression and schizophrenia. This initiative is crucial for enhancing drug discovery processes and ultimately alleviating suffering from mental health disorders. Interested applicants, including various educational and nonprofit institutions, can submit proposals until May 7, 2026, with no cap on budgets, provided they reflect actual project needs. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-168.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-168-Full-Announcement.html
    PAR-23-168.html
    The National Institute of Mental Health (NIMH) within the Department of Health and Human Services has issued a Notice of Funding Opportunity (NOFO) to support the development and validation of screening assays for discovering validated chemical hits aimed at treating mental illnesses. The funding opportunity (NOFO number PAR-23-168) emphasizes three key research stages: assay development, primary screen implementation, and hit validation. Applications are encouraged from various eligible organizations, including higher education institutions, nonprofits, and for-profit organizations, allowing diverse applicants to participate in advancing mental health research. Funding is available for projects that propose innovative biological models and screening techniques relevant to psychiatric disorders like depression and schizophrenia. The application deadlines span from June 2023 to May 2026, but only projects not proposing clinical trials are eligible. Although there is no cap on application budgets, they must reflect actual project needs. The review process will evaluate factors including significance, innovation, and the appropriateness of the research approach. The overarching goal is to enhance drug discovery processes for psychiatric treatments, ultimately contributing to NIMH's mission of alleviating suffering from mental health disorders.
    Similar Opportunities
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Research Project Grants (R01) aimed at the development of screening assays for drug candidates targeting psychiatric disorders. The primary objectives of this initiative are to stimulate research in the discovery and development of novel small molecules that can potentially treat mental illnesses, as well as to validate compounds that demonstrate desired biological activity through rigorous screening processes. This funding is crucial for advancing therapeutic options for conditions such as depression, schizophrenia, and PTSD, and it encourages applicants to align their proposals with the National Institute of Mental Health (NIMH) priorities. Interested applicants must submit their proposals by May 7, 2026, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at encouraging research into high-confidence risk factors associated with complex brain disorders such as schizophrenia, bipolar disorder, and major depression. This initiative supports exploratory developmental research (R21) to identify molecular, cellular, and circuit mechanisms involved in these disorders, utilizing diverse experimental paradigms without the necessity for prior feasibility data. The funding amount is capped at $275,000 over two years, with a maximum of $200,000 per year, and eligible applicants include a wide range of educational institutions, nonprofits, and for-profit organizations. Interested parties can find more information and application details at the NIH website, with the application deadline set for September 7, 2026.
    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can modulate biological targets relevant to mental health, aging, drug abuse, and eye diseases. The initiative seeks to stimulate the discovery and development of in vivo chemical probes, requiring applicants to have validated starting compounds for optimization and bioassays to test new analogs. This funding is crucial for advancing the understanding of brain disease mechanisms and emphasizes projects that provide insights into significant biological processes. Interested applicants can submit proposals until January 7, 2027, with no budget limit specified, although actual needs must be indicated. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the National Cooperative Drug/Device Discovery/Development Groups (NCDDG) funding opportunity, aimed at advancing innovative therapies for mental disorders through cooperative agreements. This initiative encourages applications focused on the discovery, preclinical development, and proof of concept testing of new pharmacological agents and neuromodulatory devices, with a strong emphasis on partnerships between academia and industry. The program is designed to facilitate the transition of drug and device solutions from discovery to early human trials, addressing critical mental health challenges. Interested applicants must comply with NIH registration and submission requirements, with application deadlines beginning on January 25, 2025, and funding awards potentially lasting up to five years. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-352.html.
    Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research on the biological mechanisms underlying complex brain disorders such as schizophrenia, bipolar disorder, and autism. This initiative encourages studies that explore high-confidence risk factors associated with these disorders, focusing on intracellular, transcellular, and circuit mechanisms, while emphasizing the importance of disseminating findings to enhance data resources and therapeutic target identification. Eligible applicants include a wide range of institutions, including historically black colleges, tribal colleges, and various nonprofit organizations, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and detailed information can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-024.html.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)," aimed at advancing the discovery and development of innovative treatments for mental disorders, including substance use disorders and alcohol use disorder. This initiative encourages collaborative efforts between academia and industry to support multidisciplinary research projects that focus on early-stage human studies and the development of novel therapeutic candidates and neuromodulation tools. The program is designed to complement private sector efforts and emphasizes the importance of data sharing and innovative approaches to mental health treatment challenges. Interested applicants must adhere to specific eligibility criteria and application instructions, with a submission opening date of January 25, 2025, and a total project period not exceeding five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators" through the National Cancer Institute (NCI). This initiative aims to support research focused on the identification and development of small molecules that can elucidate cancer biology and contribute to therapeutic advancements. The funding is intended for various eligible applicants, including educational institutions and non-profit organizations, with a flexible budget and a project duration of up to three years. Key deadlines include an application submission window starting January 5, 2025, and a closing date of September 7, 2026. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html.
    Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Studies of Mental Illness (Collaborative R01)" aimed at supporting multidisciplinary clinical studies focused on mental health, particularly in areas such as genetics, biomarkers, and various mental illnesses. This initiative encourages collaboration across multiple sites to enhance sample sizes and diversity in participant recruitment, specifically targeting health disparity populations. The program allows for a project period of up to five years with no explicit budget limits, although proposed budgets must be well justified. Interested applicants, including various educational and nonprofit institutions, should submit their applications by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-050.html.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) for the development and screening of assays aimed at discovering small molecules that can serve as chemical probes, drugs, or immunomodulators. This initiative seeks to support research that elucidates disease biology and therapeutic targets, particularly focusing on cancer-related applications, including the development of assays, high-throughput screening, hit validation, and optimization of lead compounds. The opportunity is open to a wide range of eligible applicants, including educational institutions, nonprofits, and tribal organizations, with no cost-sharing requirement and a project period of up to three years. Interested parties should submit their applications electronically through Grants.gov by the deadline of September 7, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Discovery of in vivo Chemical Probes for the Nervous System
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the discovery of in vivo chemical probes for the nervous system, specifically targeting novel brain mechanisms. This initiative, led by the National Institute on Aging (NIA) in collaboration with the National Eye Institute (NEI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH), seeks applicants who possess validated starting compounds for chemical optimization and bioassays to explore new analog compounds. The focus will be on developing small molecules that can enhance understanding of biological processes relevant to brain diseases, with an emphasis on innovative biological targets. Interested applicants can reach out to Dr. Paul G. Grothaus at grothausp@mail.nih.gov or call 240-688-6634 for further information, with the estimated synopsis posting date set for February 26, 2026, and a projected award date of April 5, 2027.